Company Name: |
Hangzhou MolCore BioPharmatech Co.,Ltd. |
Tel: |
+86-057181025280; +8617767106207 |
Email: |
sales@molcore.com |
Products Intro: |
Product Name:12-[(3R,4S)-4-ethylpyrrolidin-3-yl]-1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaene;dihydrochloride CAS:2050038-84-9 Purity:95%+ Remarks:MC710373
|
|
|
|
|
3H-Imidazo[1,2-a]pyrrolo[2,3-e]pyrazine, 8-[(3R,4S)-4-ethyl-3-pyrrolidinyl]-, hydrochloride (1:2) manufacturers
|
| 3H-Imidazo[1,2-a]pyrrolo[2,3-e]pyrazine, 8-[(3R,4S)-4-ethyl-3-pyrrolidinyl]-, hydrochloride (1:2) Basic information |
Product Name: | 3H-Imidazo[1,2-a]pyrrolo[2,3-e]pyrazine, 8-[(3R,4S)-4-ethyl-3-pyrrolidinyl]-, hydrochloride (1:2) | Synonyms: | 3H-Imidazo[1,2-a]pyrrolo[2,3-e]pyrazine, 8-[(3R,4S)-4-ethyl-3-pyrrolidinyl]-, hydrochloride (1:2);3H-Imidazo[1,2-a]pyrrolo[2,3-e]pyrazine;8-[(3R,4S)-4-ethyl-3-pyrrolidinyl]-3H-Imidazo[1,2-a]pyrrolo[2,3-e]pyrazine hydrochloride (1:2);8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine Hydrochloride;12-[(3R,4S)-4-ethylpyrrolidin-3-yl]-1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaene;8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine dihydrochloride;Upadacitinib Impurity 7(Dihydrochloride);8- ((3R, 4S) -4-ethylpyrrolidin-3-yl) -3H imidazolo [1,2-a] pyrrolino [2,3-e] pyrazine hydrochloride | CAS: | 2050038-84-9 | MF: | C14H18ClN5 | MW: | 291.78 | EINECS: | 845-622-0 | Product Categories: | | Mol File: | 2050038-84-9.mol | |
| 3H-Imidazo[1,2-a]pyrrolo[2,3-e]pyrazine, 8-[(3R,4S)-4-ethyl-3-pyrrolidinyl]-, hydrochloride (1:2) Chemical Properties |
| 3H-Imidazo[1,2-a]pyrrolo[2,3-e]pyrazine, 8-[(3R,4S)-4-ethyl-3-pyrrolidinyl]-, hydrochloride (1:2) Usage And Synthesis |
Uses | 8-((3R,4S)-4-Ethylpyrrolidin-3-yl)-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine Dihydrochloride is a useful intermediate in the preparation of Upadacitinib, a JAK1 inhibitor. |
| 3H-Imidazo[1,2-a]pyrrolo[2,3-e]pyrazine, 8-[(3R,4S)-4-ethyl-3-pyrrolidinyl]-, hydrochloride (1:2) Preparation Products And Raw materials |
|